3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
55
Prostatic Neoplasms
46
Glioblastoma
28
Brain Neoplasms
25
Neoplasms
23
Glioma
21
Carcinoma, Non-Small-Cell Lung
19
Lung Neoplasms
18
Carcinoma, Hepatocellular
14
Gliosarcoma
13
Colorectal Neoplasms
12
Uterine Cervical Neoplasms
11
Neoplasm Metastasis
11
Rectal Neoplasms
10
Lymphoma, Non-Hodgkin
10
Oligodendroglioma
9
Melanoma
9
Central Nervous System Neoplasms
9
Astrocytoma
9
Lymphoma
8
Head and Neck Neoplasms
8
Esophageal Neoplasms
8
Colonic Neoplasms
8
Ependymoma
7
Squamous Cell Carcinoma of Head and Neck
6
Pancreatic Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
6
Carcinoma, Renal Cell
6
Breast Neoplasms, Male
6
Ovarian Neoplasms
5
Interventions
Oxaliplatin
14
Fluorouracil
11
Capecitabine
9
Surveys and Questionnaires
8
Leucovorin
8
Irinotecan
8
Cisplatin
8
Bevacizumab
8
Standard of Care
5
Gemcitabine
5
Drug Therapy
4
S 1 (combination)
3
Radiotherapy
3
Nivolumab
3
Interviews as Topic
3
IFL protocol
3
Educational Status
3
Cyclophosphamide
3
Colonoscopy
3
Blood Specimen Collection
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
tivozanib
2
pembrolizumab
2
Taxes
2
Remote Patient Monitoring
2
Pemetrexed
2
Panitumumab
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Neoplasms
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT01816607
2018-11-19
OxyTarget
University Hospital, Akershus
Completed
192 enrolled